Literature DB >> 1984455

Evidence for the targeting by 2-oxo-dehydrogenase enzymes in the T cell response of primary biliary cirrhosis.

J Van de Water1, A A Ansari, C D Surh, R Coppel, T Roche, H Bonkovsky, M Kaplan, M E Gershwin.   

Abstract

Primary biliary cirrhosis (PBC) is a chronic autoimmune liver disease that includes the presence of lymphoid infiltrates in portal tracts, high titer autoantibodies against pyruvate dehydrogenase-E2 (PDH-E2) and branched chain ketoacid dehydrogenase-E2 (BCKD-E2), and biliary tract destruction. The mechanism by which the autoimmune response is induced, the specificity of damage to the biliary epithelium, and the role of T cells in PBC are still unknown. To address these issues, we have taken advantage of a mouse mAb, coined C355.1, and studied its reactivity against a panel of liver tissue from normal subjects as well as a panel of liver specimens from patients with PBC, progressive sclerosing cholangitis, and chronic active hepatitis (CAH). C355.1, much like human autoantibodies to PDH-E2, reacts exclusively by immunoblotting with PDH-E2, binds to the inner lipoyl domain of the protein, and inhibits PDH-E2 activity in vitro. In addition, we have also attempted to develop cloned T cell lines that react with PDH-E2 and/or BCKD-E2 using liver biopsies from patients with PBC, compared with CAH. Although monoclonal C355.1 produced typical mitochondrial fluorescence on sections of normal liver, pancreas, lung, heart, thyroid, and kidney, it produced a distinct and intense reactivity when used to stain the bile ducts of patients with PBC. Nine of 13 PBC liver biopsies studied herein contained bile ducts on light microscopy, all of which reacted intensely at a 1:100 culture supernatant dilution of monoclonal C355.1. In contrast, although bile ducts of liver specimens from normals, CAH, and progressive sclerosing cholangitis also reacted with C355.1, such reactivity was exclusively mitochondrial and readily detectable only at a dilution of 1:2. More importantly, we generated CD4+, CD8-, alpha beta TCR+ cloned T cell lines from patients with PBC, but not from CAH, that produced IL-2 specifically in response to PDH-E2 or BCKD-E2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984455

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

Review 1.  Primary biliary cirrhosis. Connecting molecular biology to clinical medicine.

Authors:  S Reynoso-Paz; R L Coppel; Y Nakanuma; M E Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis.

Authors:  T Yamano; T Higashi; K Nouso; H Nakatsukasa; K Kariyama; E Yumoto; Y Kobayashi; K Yamamoto; H Iwagaki; T Yagi; T Tanimoto; M Kurimoto; N Tanaka; T Tsuji
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Authors:  Y Bar-Dayan; M E Gershwin; Y Levi; H Amital; Y Shoenfeld
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

4.  Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.

Authors:  Roberto Bellucci; Sabine Oertelt; Meagan Gallagher; Sigui Li; Emmanuel Zorn; Edie Weller; Fabrice Porcheray; Edwin P Alyea; Robert J Soiffer; Nikhil C Munshi; M Eric Gershwin; Jerome Ritz
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

5.  Ursodeoxycholic acid treatment lowers the serum level of antibodies against pyruvate dehydrogenase and influences their inhibitory capacity for the enzyme complex in patients with primary biliary cirrhosis.

Authors:  K E Kisand; A L Karvonen; M Vuoristo; M Färkkilä; J Lehtola; J Inkovaara; K V Kisand; T Miettinen; K Krohn; R Uibo
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

6.  Identification of an Epitope from Adenine Nucleotide Translocator 1 That Induces Inflammation in Heart in A/J Mice.

Authors:  Rakesh H Basavalingappa; Chandirasegaran Massilamany; Bharathi Krishnan; Arunakumar Gangaplara; Guobin Kang; Vahid Khalilzad-Sharghi; Zhongji Han; Shadi Othman; Qingsheng Li; Jean-Jack Riethoven; Raymond A Sobel; David Steffen; Jay Reddy
Journal:  Am J Pathol       Date:  2016-12       Impact factor: 4.307

Review 7.  The immunology of primary biliary cirrhosis: the end of the beginning?

Authors:  J M Palmer; J A Kirby; D E J Jones
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of autoimmune cholangitis.

Authors:  P Michieletti; I R Wanless; A Katz; P J Scheuer; S J Yeaman; M F Bassendine; J M Palmer; E J Heathcote
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

9.  Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2).

Authors:  S Cha; P S Leung; J Van de Water; K Tsuneyama; R E Joplin; A A Ansari; Y Nakanuma; P J Schatz; S Cwirla; L E Fabris; J M Neuberger; M E Gershwin; R L Coppel
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

10.  Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis.

Authors:  S Cha; P S Leung; M E Gershwin; M P Fletcher; A A Ansari; R L Coppel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.